Literature DB >> 29299407

Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study.

Aaron Lisberg1, Edward B Garon1.   

Abstract

Entities:  

Year:  2017        PMID： 29299407      PMCID： PMC5750165          DOI： 10.21037/tlcr.2017.10.16

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  9 in total

1.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

2.  Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).

Authors:  Saulius Cicènas; Sarayut Lucien Geater; Petar Petrov; Yevgeniy Hotko; Gregory Hooper; Fan Xia; Nadejda Mudie; Yi-Long Wu
Journal:  Lung Cancer       Date:  2016-10-20       Impact factor: 5.705

3.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

4.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors:  Marina Chiara Garassino; Olga Martelli; Massimo Broggini; Gabriella Farina; Silvio Veronese; Eliana Rulli; Filippo Bianchi; Anna Bettini; Flavia Longo; Luca Moscetti; Maurizio Tomirotti; Mirko Marabese; Monica Ganzinelli; Calogero Lauricella; Roberto Labianca; Irene Floriani; Giuseppe Giaccone; Valter Torri; Alberto Scanni; Silvia Marsoni
Journal:  Lancet Oncol       Date:  2013-07-22       Impact factor: 41.316

5.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  F A Shepherd; J Dancey; R Ramlau; K Mattson; R Gralla; M O'Rourke; N Levitan; L Gressot; M Vincent; R Burkes; S Coughlin; Y Kim; J Berille
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

6.  EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Authors:  Pascale Tomasini; Solenn Brosseau; Julien Mazières; Jean-Philippe Merlio; Michèle Beau-Faller; Jean Mosser; Marie Wislez; L'Houcine Ouafik; Benjamin Besse; Isabelle Rouquette; Didier Debieuvre; Fabienne Escande; Virginie Westeel; Clarisse Audigier-Valette; Pascale Missy; Alexandra Langlais; Frank Morin; Denis Moro-Sibilot; Gérard Zalcman; Fabrice Barlesi
Journal:  Eur Respir J       Date:  2017-08-10       Impact factor: 16.671

7.  Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Authors:  Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol
Journal:  Lancet       Date:  2014-06-02       Impact factor: 79.321

8.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245
  9 in total
  1 in total

1.  Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.

Authors:  Rintu Thomas; Zhang Weihua
Journal:  Front Oncol       Date:  2019-08-23       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.